Last updated on March 2018

Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration


Brief description of study

This trial evaluates efficacy and safety of inhaled molgramostim (rhGM-CSF) in 45 patients with pneumonia associated acute respiratory distress syndrome (ARDS). A third of the patients will receive 150 mcg inhaled molgramostim, another third 450 mcg and the remaining third will receive inhaled placebo for 3 days. The patients will be followed for 28 days.

Clinical Study Identifier: NCT02595060

Contact Investigators or Research Sites near you

Start Over

Susanne Herold, MD, PhD

Universities of Marburg and Giessen Lung Center
Giessen, Germany
  Connect »

Kai Zacharowski, Prof. Dr. Dr., ...

Universit tsklinikum Frankfurt, Klinik f r An sthesiologie, Intensivmedizin und Schmerztherapie
Frankfurt, Germany
  Connect »

Tobias Welte, Prof. Dr., MD

Medizinische Hochschule Hannover, Klinik f r Pneumologie
Hannover, Germany
  Connect »

Michael Bauer, MD, Prof. Dr

Universit tsklinikum Jena, Klinik f r An sthesiologie und Intensivmedizin
Jena, Germany
  Connect »

Hinnerk Wulf, MD, Prof. Dr

University Hospital Marburg, Department of Anaesthesiology and Intensive Care Medicine
Marburg, Germany
  Connect »

Stefan Kluge, MD, Prof. Dr.

Universit tsklinikum Hamburg-Eppendorf, Klinik f r Intensivmedizin
Hamburg, Germany
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.